anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
N6-methyladenosine (m6A) modification has been implicated in many cell processes and diseases. YTHDF1, a translation-facilitating m6A reader, has not been previously shown to be related to allergic airway inflammation. Here, we report that YTHDF1 is highly expressed in allergic airway epithelial cells and asthmatic patients and that it influences proinflammatory responses. CLOCK, a subunit of the circadian clock pathway, is the direct target of YTHDF1. YTHDF1 augments CLOCK translation in an m6A-dependent manner. Allergens enhance the liquid-liquid phase separation (LLPS) of YTHDF1 and drive the formation of a complex comprising dimeric YTHDF1 and CLOCK mRNA, which is distributed to stress granules. Moreover, YTHDF1 strongly activates NLRP3 inflammasome production and interleukin-1β secretion leading to airway inflammatory responses, but these phenotypes are abolished by deleting CLOCK. These findings demonstrate that YTHDF1 is an important regulator of asthmatic airway inflammation, suggesting a potential therapeutic target for allergic airway inflammation.
The invention discloses a fusion expression plectasin, a preparation method and application thereof, wherein the amino acid sequence of the recombinant plectasin is SEQ ID NO. 1; the nucleotide sequence designed according to the preferred codon of the escherichia coli is SEQ ID NO. 2. The invention constructs escherichia coli BL21(DE3) host bacteria capable of expressing plectasin-thioredoxin fusion protein by using prokaryotic expression vectors. The strain is subjected to amplification culture, induced expression is carried out through isopropyl-beta-D-thiogalactoside, thalli are obtained through centrifugation, supernatant is obtained through centrifugation after thalli are cracked, myceliophycin fusion protein is obtained through affinity chromatography purification, and the growth of gram-positive staphylococcus aureus, streptococcus pneumoniae and the like can be remarkably inhibited without removing thioredoxin through enzyme digestion. The invention can have obvious bacteriostatic action without enzyme digestion to remove the fusion protein, thereby greatly reducing the production cost.
Aortic Stenosis/Hypertrophic Cardiomyopathy: As with all vasodilators, enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle.  


Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including enalapril maleate, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.  


In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.  


Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when enalapril maleate has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or enalapril maleate may be required.  


Evaluation of patients with hypertension or heart failure should always include assessment of renal function. (See DOSAGE AND ADMINISTRATION.)  
Hyperkalemia: Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in heart failure, hyperkalemia was observed in 3.8 percent of patients but was not a cause for discontinuation.  


Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassiumsparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with enalapril maleate. (See Drug Interactions.)  


Cough: Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.  


Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.
A blood glucose monitoring system with a graphical user interface (GUI) and methods of controlling the system and performing episodic blood glucose testing using the GUI are disclosed. The system can comprise the GUI, an output display for displaying the GUI, user interfaces, a memory and a processor. An episodic blood glucose testing protocol can be programmed into the processor using the user interfaces and automatically saved into memory. A user can be alerted to test blood glucose levels based on the inputted testing protocol by the display of an alert icon on the GUI. Blood glucose level results can be received, displayed on the GUI along with a range icon and automatically saved into memory. Statistics of the saved blood glucose results can be calculated by the processor and saved into memory. The statistics can be retrieved for display on the GUI when prompted by the user.
Anticipated 30 subjects will be enrolled to receive Endostar, Gemcitabine and Docetaxel. Endostar at a dosage of 7.5 mg/m2 will be administered on Day 1-14 of each cycle. Gemcitabine (1000 mg/m2) will be administered on Day 1 and Day 8 of each cycle. Docetaxel (75 mg/m2) will be administered on Day 2 of each cycle. An individual cycle of therapy will be defined as a 3-week (21-day) period. Cycles will be repeated every 3 weeks. Multiple cycles may be administered until the subject is PD or until a maximum of 6 cycles. Time-to-progression (TTP) will be assessed using the Kaplan Meier method. Overall response rate (ORR) as well as individual categories of response (CR, PR, SD, and PD) will be determined using RECIST (v1.1). Evaluation of 1- and 2-year overall survival will also be performed. Safety measures will be recorded using the NCI-CTCAE (v4.0).
This study comprised 3 parallel arms corresponding to 3 types of stimulation: active stimulation of M1, active stimulation of DLPFC-pcTBS, and sham stimulation (of M1 or DLPFC). Volunteers were randomly assigned to the 3 arms. In the first part, these volunteers participated in 2 experimental sessions 1 weeks apart, in which we compared the effects of naloxone and placebo (saline), administered according to a randomized, double-blind crossover design, on pcTBS-induced analgesia. Each experimental session started with the determination of baseline pain intensity and cortical excitability as well as plasma opioid peptide concentrations. Ten minutes before pcTBS (of M1, DLPFC, or sham), the volunteer received an intravenous bolus followed by a continuous infusion of either placebo (ie, saline) or naloxone, which was continued throughout the rTMS session (2 minutes). The participant was then allowed to rest for 60 minutes. Posttreatment pain intensity, cortical excitability and plasma opioid peptide concentrations will be determined by the same procedure used at baseline.In the second part, ketamine will be delivered the same as the first part.
Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT "KAKETSUKEN" Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age.
The initial success and widespread adoption of endovascular aneurysm repair (EVAR) for the treatment of abdominal aortic aneurysms have been tempered by numerous reports of secondary interventions and increased long-term mortality compared with open repair. Over the past decade, several studies on postoperative sac dynamics after EVAR have suggested that the presence of sac regression is a benign feature with a favorable prognosis. Conversely, increasing sacs and even stable sacs can be indicators of more unstable sac behavior with worse outcomes in the long-term. Endoleaks were initially perceived as the main drivers of sac behavior. However, the observation that sac regression can occur in the presence of endoleaks, and vice versa - increasing sacs without evidence of endoleak - on imaging studies, suggests the involvement of other contributing factors. These factors can be divided into anatomical factors, patient characteristics, sac thrombus composition, and device-related factors. The shift of interest away from especially type 2 endoleaks is further supported by promising results with the use of EndoAnchors regarding postoperative sac behavior. This review provides an overview of the existing literature on the implications and known risk factors of post-EVAR sac behavior, describes the accurate measurement of sac behavior, and discusses the use of EndoAnchors to promote sac regression.
<P>PROBLEM TO BE SOLVED: To obtain a moisturizing plant extract with sustainable moisture retaining effect for many hours, an external preparation, a cosmetic, a bathing agent and a detergent composition.  <P>SOLUTION: The moisturizing plant extract comprises an extract of a mixture of Prunus jamasakura Siebold, Platycodon grandiflorum A. De Candolle, Bupleurum falcatum Linne, Cnidium officinale Makino, Poria cocos Wolf, Saposhnikovia divaricata Schischkin, Aralia cordata Thunberg, Glycyrrhiza glabra Linne, Schizonepeta tenuifolia Briquet and Zingiber officinale Roscoe. The cosmetic, the bathing agent and the detergent composition each comprises the extract. The product made by decocting a prescribed ratio of the above-mentioned crude medicine has the same composition as that of a medicine which is called Juumihaidokutou in the traditional Chinese medical science and is regarded effective for purulent dermatosis, acute dermatosis at initial stage, nettle rash, acute eczema, athlete's foot, etc. The extract of the mixture of these crude medicines contains a moisturizing plant component with sustainable moisture retaining effect for many hours and exhibits effects, by external use, on preventing, mitigating or ameliorating dry skin, rough skin, crack, chapped skin, dandruff, itching and inflammatory diseases, and on the hair, in curing dryness, looseness, split hair and broken hair and imparting gloss, and the like.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND The purpose of this study was to investigate the effects of eyeball exercise and cervical stabilization programs to patients with chronic neck pain, tension-type headache (TTH), and forward head posture (FHP). MATERIAL AND METHODS The design of this study was a randomized controlled trial. A total of 40 participants were randomly divided into 2 groups: the experimental group (n=20) and the control group (n=20). Both groups received cervical manual therapy and biofeedback-guided stabilization exercises (30 min/session, 3 sessions/week, 6 weeks). In addition to the regular treatments, the participants in the experimental group also performed eyeball exercises for 20 minutes per session, 3 sessions per week, for a total of 6 weeks. Changes in neck pain (numeric rating scale, NRS), neck disability index (NDI), quality of life (Short Form-12 Health Survey Questionnaire, SF-12), headache impact test-6 (HIT-6), craniovertebral angle (CVA), cranial rotation angle (CRA), and muscle tone were measured. RESULTS Both groups showed significant improvements in NRS, NDI, SF-12, HIT-6 scores, CVA, CRA, and muscle tone (p<0.05). The experimental group had significant differences in NDI, SF-12, HIT-6 scores, and suboccipital muscle tone compared to the control (p<0.05). CONCLUSIONS Combining the eyeball exercise program with commonly used manual therapy and stabilization exercises for patients with chronic neck pain can help reduce nerve compression and promote muscle relaxation in the eye and neck areas. The method is thus proposed as an effective intervention to enhance function and quality of life in patients with chronic neck pain patients, TTH, and FHP.
The subject matter of the present invention is a composition, in particular a cosmetic composition, in the form of an emulsion comprising at least one polyester resulting from the esterification, with a polycarboxylic acid, of an ester of an aliphatic hydroxycarboxylic acid comprising at least two hydroxyl groups and at least one non-ionic derivative of cellulose comprising one or more hydrophobic substituents having from 8 to 30 carbon atoms. The subject matter of the present invention is also a composition, in particular a cosmetic composition, in the form of an emulsion comprising at least one active agent chosen from C-glucoside derivatives, in particular C-beta-D-xylopyranoside-2-hydroxy­propane, and cucurbic acid derivatives, such as the sodium salt of (3-hydroxy-2-pentylcyclopentyl)acetic acid, at least one pasty fatty substance, and at least one non-ionic derivative of cellulose comprising one or more hydrophobic substituents having from 8 to 30 carbon atoms. The invention makes it possible to obtain emulsions which contain pasty fatty substances which are stable, even without the use of an emulsifying surfactant or with a low content of emulsifying surfactant (for example less than 3%), and which provide a pleasant sensory feel, even when the composition comprises a high content of pasty fatty substances. The present invention also makes it possible to obtain emulsions which contain active agents chosen from C‑glucoside derivatives and cucurbic acid derivatives which are stable, even without the use of an emulsifying surfactant or with a low content of emulsifying surfactant (for example less than 3%), and which provide a pleasant sensory feel, even when the composition comprises a high content of these active agents. The composition according to the invention provides an excellent experience for the senses, with neither a rough nor greasy nor tacky effect and with no pilling effects. Furthermore, it makes it possible to reinforce the perception of effectiveness by virtue of immediate effects felt as soon as the product is applied: nutritive, soothing, moisturizing effects.
Acetaminophen and codeine phosphate tablets contain codeine, a substance with a high potential for abuse similar to other opioids, including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. Acetaminophen and codeine phosphate tablets can be abused and are subject to misuse, addiction, and criminal diversion [see WARNINGS].

All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful, or potentially harmful, consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care providers. “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

Acetaminophen and codeine phosphate tablets, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of Acetaminophen and Codeine Phosphate Tablets \- Acetaminophen and codeine phosphate tablets are for oral use only. Abuse of acetaminophen and codeine phosphate tablets poses a risk of overdose and death. The risk is increased with concurrent use of acetaminophen and codeine phosphate tablets with alcohol and other central nervous system depressants.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
Cutaneous granulomatous reactions are diverse, both from the clinical and the pathological perspective. Most underlying pathophysiological aspects remain elusive. Interstitial granulomatous dermatitis and palisaded neutrophilic and granulomatous dermatitis have been claimed to be reactions to systemic disorders, such as infectious, inflammatory, or neoplastic conditions. Recently, the overarching term "reactive granulomatous dermatitis" has been coined to unify both entities. We herein report two cases of reactive granulomatous dermatitis presenting with the widely known, albeit infrequent "rope sign" and provide clinicopathological correlation. The two patients included a 53-year-old woman with enlarging erythematous plaques and underlying palpable cords on both sides of trunk near axillae (rope sign), and a 51-year-old woman with personal history of rheumatoid arthritis and a palpable cord on the left aspect of the trunk. Pathological findings were compatible with reactive granulomatous dermatitis in both cases. In conclusion, the rope sign represents a strikingly infrequent but decisive diagnostic clue of reactive granulomatous dermatitis.
The present invention discloses wound plaster of yannan Baiyao and a preparing method thereof, which relates to a Chinese medicine preparation of a plaster form, which is a novel dosage form of yunnan Baiyao. The present invention comprises medicine, an adhesive tape and a medicated core, and is characterized in that the medicine comprises 65 grams to 105 grams of yunnan baiyao powder, 0.5 gram to 1.5 grams of tween-80, 0.6 gram to 1.0 gram of borneol and 70 ml to 130 ml of water for preparing 1200 pieces of yunnan Baiyao wound plaster. Compared with the existing general wound plaster, the present invention can sufficiently keep and exert the efficiency of tradition medicine of promotion of blood circulation for removing blood stasis, detumescence, alleviation of pain and hemostasis, healing of hurt of yunnan Baiyao. The present invention has good effects for hemostasis of small wounds, analgesia, antiinflammation and healing of wound, and the cure rate is 100%. The present invention has the advantages of portability, fast effect taking and outstanding curative effects. Because the yunnan Baiyao powder has the efficiency of promotion of blood circulation for removing blood stasis and regeneration of the tissue, the wounds can recover to level.
PURPOSE:To provide a bronchodilator containing 2-(4-carboxybenzamide)-4- aminobenzoic acid ethyl ester or its salt as an active component. CONSTITUTION:The objective bronchodilator contains 2-(4-carboxybenzamido)-4- aminobenzoic acid ethyl ester or its salt as an active component. The agent is useful as a remedy for asthma, etc. It is administered at a dose of several mg - several g, preferably 50-300mg daily for adult preferably by oral administration. The carrier for the drug preparation is preferably lactose, sorbitol, mannitol, potato starch, etc. If necessary, the drug composition is incorporated with a lubricant such as calcium stearate, carbowax, polyethylene glycol, etc.
The invention describes novel nitrosated and/or nitrosylated nebivolol, novel nitrosated and/or nitrosylated metabolites of nebivolol and novel compositions comprising at least one nitrosated and/or nitrosylated nebivolol and/or at least one nitrosated and/or nitrosylated metabolite of nebivolol, and optionally, at least one nitric oxide donor and/or at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular disease or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The invention also provides novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.